Mutant Fms-Like Tyrosine kinase-3 (FLT3), which is expressed in the leukemic cells of a subpopulation of acute myeloid leukemia (AML) patients, represents an attractive target for the therapy of AML. There are several FLT3 inhibitors presently in clinical trials with sufficient efficacy and toxicity features to warrant further testing in combination with standard therapies. However, the transient and partial responses observed in AML patients treated with FLT3 inhibitors, coupled with the discovery of drug-resistant leukemic blast cells in AML patients, have made resistance to FLT3 inhibitors a growing concern. In this study, we provide an overview of the role of mutant FLT3 in AML, FLT3 inhibitors under clinical and preclinical investigation, mechanisms of resistance to FLT3 inhibitors, and possible therapeutic approaches to overcoming this resistance.
Introduction
Acute myeloid leukemia (AML) is a hematological malignancy marked by aberrant growth of myeloid precursor cells and a block in cellular differentiation at various stages. Most AML patients have underlying genetic mutations that cause the production of precursor cells characterized by either a block in differentiation, aberrant and accelerated growth, or a combination of both (Olsson et al., 1996; Tanaka et al., 1997; Pabst et al., 2001) .
Approximately 30% of AML patients, and a subset of acute lymphoblastic leukemia (ALL) patients, express a mutated form of the class III receptor tyrosine kinase (RTK), Fms-Like Tyrosine kinase-3 (FLT3) (STK-1, human Stem Cell Tyrosine Kinase-1; or FLK-2, Fetal Liver Kinase-2) (Stirewalt and Radich, 2003) . Constitutively activated FLT3 occurs most frequently as internal tandem duplications (ITDs) within the juxtamembrane domain (Nakao et al., 1996) , and is observed in B20-25% of AML patients, however in o5% of patients with myelodysplastic syndrome (Nakao et al., 1996; Horiike et al., 1997; Kiyoi et al., 1998; Kondo et al., 1999; Rombouts et al., 2000) . Gain-of-function FLT3 occurs less frequently as point mutations in the activation loop (in B7% of AML cases), and is often found at position 835 (Yamamoto et al., 2001) . Occurring less frequently are additional point mutations in the kinase domain, including N841I (Jiang et al., 2004) and Y842C (Kindler et al., 2005) . In addition, novel activating point mutations have been identified in a 16 amino-acid stretch of the FLT3 juxtamembrane, which generally have a weaker transforming potential than FLT3-ITD and tyrosine kinase domain mutants (Reindl et al., 2006) . A diagram of FLT3 mutations is shown in Figure 1 .
Transplantation of murine bone marrow cells infected with a retrovirus expressing an FLT3-ITD mutant has been shown to result in the development of a rapidly lethal myeloproliferative disease in mice (Kelly et al., 2002a) . This myeloproliferative syndrome occurs in the absence of any significant block in differentiation of granulocyte lineage cells, suggesting that the primary role of mutant FLT3 in AML might be to enhance the viability and growth of primitive myeloid cells.
For the development of full and progressive AML, mutant FLT3 likely cooperates with other oncogenes associated with AML, such as PML/ RARa (t(15; 17) or AML1/ETO (t(8;21), the major role of which is to block differentiation. Approximately 10% of AML patients harbor translocations involving the mixed lineage leukemia (MLL, HRX, ALL-1) gene, found on chromosome 11q23 (Dimartino and Cleary, 1999) . Chromosomal translocations such as MLL-AF9 (t(9;11)), 17) ) and AML1- ETO (t(8; 21) ) result in the generation of chimeric fusion oncogenes, the acquisition of which represents the first phase of leukemogenesis; additional mutations are required for complete leukemia development (Greaves and Wiemels, 2003) . For instance, activating FLT3 mutations have been detected in some AMLs that harbor MLL-AF9 translocations (Gilliland and Griffin, 2002; Libura et al., 2003) .
Mutant FLT3 and cell signaling
The survival advantage of leukemic cells driven by mutant FLT3 is to a large extent because of its activation of three major intracellular signaling pathways, PI3K//PTEN/Akt/mTOR, RAS/Raf/MEK/ERK and Jak/STAT (Kornblau et al., 2006) . The significant cross-talk between the signaling mediators of these pathways warrants consideration of the use of a multitargeted therapeutic approach for mutant FLT3-positive AML.
FLT3-ITD mutations are associated with activation of AKT, the downstream effector of PI3K (Brandts et al., 2005) , as well as STAT5 (Rocnik et al., 2006) . Mutant FLT3-positive AML cells are killed by rapamycin, because of its inhibition of mTOR, another downstream effector of the PI3K/Akt signaling pathway (Recher et al., 2005) . Similarly, AML cells expressing mutant FLT3 are killed by inhibition of the mutant FLT3 chaperone, heat-shock protein 90 (Hsp90), which interferes with JAK/STAT, RAS/Raf/MEK/ERK and PI3K/Akt signaling (Al Shaer et al., 2008) . A schematic of FLT3 signaling is shown in Figure 2 .
Kinase inhibitors under clinical investigation for mutant FLT3-positive AML activity
Several inhibitors of FLT3 currently under clinical investigation exhibit adequate efficacy and safety profiles to be considered for further development as therapeutics in combination with standard therapy for AML. For instance, a Phase III trial is presently recruiting patients for investigation of the N-indolocarbazole, PKC412 (midostaurin; N-benzoyl-staurosporine, Novartis Pharma AG, Basel, Switzerland), a broad-spectrum, orally bioavailable inhibitor that targets FLT3, plateletderived growth factor b (PDGFRb), c-KIT and c-FMS (Weisberg et al., 2002) . The trial will investigate induction (daunorubicin/cytarabine) and consolidation (high-dose cytarabine) chemotherapy plus PKC412 or placebo in newly diagnosed, mutant FLT3-positive AML patients under the age of 60 years. There is also an ongoing Phase I/II trial investigating the combination of PKC412 and 5-azacitadine in elderly AML patients, and an ongoing Phase I trial investigating the effects of RAD001 in combination with PKC412 in (Stone et al., 2005b) . Clinical responses were complete (CR) in all the mutant FLT-positive patients treated, and side effects were transient and/or reversible (Stone et al., 2005b) . In a Phase II clinical trial, PKC412 was generally well tolerated, with a decrease in peripheral blast counts observed in roughly a third of PKC412-treated relapsed/refractory AML patients, and a median response duration of 13 weeks (Stone et al., , 2005a . The hematological response rate in advanced AML patients treated with PKC412 was comparable to that of chronic myeloid leukemia (CML) blast crisis patients receiving imatinib.
Also in clinical trials is the orally administered indolocarbazole alkaloid, CEP-701 (lestaurtinib; Cephalon) , which targets TrkA and vascular endothelial growth factor receptor (VEGFR) and inhibits the growth of FLT3-ITD-expressing cells . Relapsed/refractory AML patients showed transient clinical responses to CEP-701 in early clinical trials (Smith et al., 2004) . Transient clinical responses were also observed in a Phase II trial for older AML patients not eligible for intensive chemotherapy (Knapper et al., 2006) . CEP-701 is presently being investigated in the United Kingdom in combination with chemotherapy in a Phase III clinical trial for AML patients harboring wild-type FLT3 and mutant FLT3. There is an ongoing Phase II trial investigating CEP-701 in AML patients, and an ongoing Phase I/II trial investigating the combination of CEP-701 in combination with cytarabine and idarubicin in younger patients with relapsed or refractory AML. In addition to AML, CEP-701 has also been investigated in a Phase II trial for prostate cancer, and is under investigation in a Phase I trial for high-risk neuroblastoma.
Investigated in Phase I and II clinical trials for AML patients that are not candidates for approved therapy is KW-2449 (Pratz and Levis, 2008; Pratz et al., 2009; Shiotsu et al., 2009) , for the purpose of determining its maximum tolerated dose. In a Phase I trial, KW-2449 treatment led to transient decreases in peripheral blast counts (Cortes et al., 2008; Pratz and Levis, 2008; Pratz et al., 2009 (Fiedler et al., 2005; Kancha et al., 2007; O'Farrell et al., 2003a, b) , as well as the piperazinyl quinazoline MLN518 (tandutinib; CT53518; Millennium, Cambridge, MA, USA) (Kelly et al., 2002b; Cheng and Paz, 2008) . There is presently an ongoing Phase I/II trial investigating SU11248 combined with standard chemotherapy in mutant FLT3-positive AML patients over the age of 60 years.
Additional novel FLT3 inhibitors in early development include the N-(4-(3-amino-1H-indazol-4yl)phenyl-N1(2-fluoro-5-methylphenyl) urea ABT-869 (Albert et al., 2006; Shankar et al., 2007; Zhou et al., 2008) , which is a multitargeted inhibitor with activity toward FLT3, PDGFR, KIT and KDR; the benzimidalzolequinoline CHIR-258 (TKI258; Chiron, Emeryville, CA, USA), which has among its targets FLT3, KIT, FMS, VEGFR and FGFR (Lopes de Menezes et al., 2005) and is a promising antimyeloma drug (Trudel et al., 2005) presently in Phase I clinical trials for multiple myeloma, mixed solid tumors and AML; the hydroxystyrylacrylonitrile LS104 (Kasper et al., 2008) , which is in a Phase I clinical trial for patients with refractory/ relapsed hematological malignancies; and AP24534 (Ariad, Cambridge, MA, USA), a multitargeted kinase inhibitor with activity against FLT3, KIT and FGFR (Rivera et al., 2008) , and which is in Phase I clinical trials for CML and other hematological malignancies. It is important to note that thus far, no selective FLT3 inhibitor has been developed that would allow the study of FLT3 exclusively as a target.
Dasatinib (BMS-354825; Bristol Myers Squibb, New York, NY, USA) targets multiple proteins, and this property might very well increase its versatility in terms of disease targets. Dasatinib (BMS-354825; Bristol Myers Squibb) is presently well known as being a highly potent, orally active inhibitor of Abl that inhibits a wide panel of BCR-ABL point mutants that are resistant to imatinib (Shah et al., 2004; Burgess et al., 2005; O'Hare et al., 2005) . Dasatinib also inhibits SRC and SRC-family kinases, including FGR, FYN, HCK, LCK, LYN, SRC and YES (Das et al., 2006) , as well as a potent inhibitor of KIT, PDGFR and Ephrin RTKs (Melnick et al., 2006) . Dasatinib received accelerated approval by the US Food and Drug Administration (FDA) for treatment of imatinib resistant/intolerant adult CML, as well as drug-resistant Ph þ ALL.
A recent study showed activity of dasatinib, although at a relatively high concentration (B1 mM), toward AML blasts and mutant FLT3 and mutant KIT (Guerrouahen et al., 2010) . Thus, inhibitors such as dasatinib, which have a broad spectrum of protein targets, might be a consideration as a therapeutic alternative for treatment of mutant FLT3-positive AML.
A Phase I trial, which has not yet started recruiting patients, will investigate the combination of dasatinib and all-trans retinoic acid in relapsed/refractory elderly AML patients. An ongoing Phase I/II trial is investigating dasatinib in patients with newly diagnosed corebinding factor AML.
Another multi-targeted inhibitor, the biaryl urea compound, sorafenib (BAY 43-9006, Nexavar; Bayer AG, Leverkusen, Germany), which was initially developed as a RAF inhibitor and has been FDA approved for advanced renal cancer and advanced liver cancer, has activity against VEGFR-2, VEGFR-3, PDGFRb, and KIT, FLT3-ITD and D835G (Auclair et al., 2007; Lierman et al., 2007; Zhang et al., 2008) . Sorafenib potently inhibits FLT3-ITD with an IC50 in the low nanomolar range (Auclair et al., 2007; Kancha et al., 2007) . In a Phase I clinical trial for patients with refractory or relapsed AML, sorafenib reduced the percentage of leukemia blasts in the bone marrow and peripheral blood of FLT3-ITD-positive AML patients (Zhang et al., 2008) . Compassionate use of sorafenib as monotherapy before or after allogeneic stem cell transplantation in relapsed or refractory FLT3-ITDpositive AML induced clinically significant and rapid responses in patients (Metzelder et al., 2009) .
A phase II trial investigating the efficacy of sorafenib plus standard primary therapy for newly diagnosed elderly AML patients has been completed. There are several ongoing Phase I or Phase I/II trials testing sorafenib in combination with other agents, such as idarubicin, cytarabine, clofarabine or vorinostat in poor-risk or refractory or relapsed AML. One Phase I trial, which has not yet started recruiting patients, will investigate granulocyte colony stimulating factor (G-CSF) and Plerixafor plus sorafenib for mutant FLT3-positive AML.
A novel and potent second-generation FLT3 inhibitor, AC220 (Chao et al., 2009; Zarrinkar et al., 2009) , exhibits higher potency and selectivity when compared with first-generation FLT3 inhibitors CEP-70, MLN-518, PKC412, sorafenib and sunitinib. In animal models, AC220 showed efficacy at 1 mg/kg administered orally, once daily. AC220 is presently under investigation in an ongoing Phase II trial investigating its efficacy as monotherapy in FLT3-ITD-positive AML, as well as an ongoing Phase I trial studying its effects in relapsed/ refractory AML patients harboring wild-type as well as mutant FLT3.
A listing of these inhibitors, as well as additional novel FLT3 inhibitors that are in preclinical development, is provided in Table 1 .
Causes of resistance to FLT3 inhibitors
The development of resistance in leukemia patients to treatment with targeted tyrosine kinase inhibitors is a growing area of concern. Generally, FLT3 inhibitors tested thus far clinically induce only partial and transient responses in patients when used as single agents. As an example, Phase I testing of KW-2449 showed only transient inhibition of FLT3 in patients to o20% of baseline (Pratz et al., 2009) . It is anticipated that the limited clinical efficacy of FLT3 inhibitors may be due to their inability to elicit sustained, complete responses in patients (Chu and Small, 2009 ). This suggests a need for development of novel agents that can either be used effectively alone or combined with other agents to suppress disease progression and prolong lifespan.
There are multiple factors that have been identified as possible underlying causes of resistance to FLT3 inhibitors. A schematic of resistance mechanisms is shown in Figure 3 .
FLT3 mutations that interfere with drug binding
An important mechanism of resistance to FLT3 inhibitors is acquired point mutations in the molecular targets (Shah et al., 2002; Cools et al., 2003) . For example, resistance to PKC412 in patients has been attributed to preexisting or acquired mutations in the kinase domain of FLT3 (Heidel et al., 2006) . This is reminiscent of the most frequent mechanism of resistance to the ABL inhibitor, imatinib: point mutations in the BCR-ABL gene. Such point mutations result in amino-acid changes in the catalytic domain of the BCR-ABL protein that reduce the ability of imatinib to bind and inhibit the tyrosine kinase activity of the enzyme (Gorre et al., 2001) .
A screening assay used to study resistance profiles of three FLT3 inhibitors, PKC412, SU5614 and sorafenib, showed nonoverlapping mechanisms of resistance for the three inhibitors (von Bubnoff et al., 2009) , which is in contrast to the overlapping resistance profiles displayed for ABL inhibitors, namely imatinib, nilotinib and dasatinib, which, for instance, all show resistance to the T315I gatekeeper mutation Von Bubnoff et al., 2006; Ray et al., 2007) . Specifically, FLT3-ITD-expressing cells resistant to PKC412 only showed mutations within tyrosine kinase domain 1 at residue N676 (von Bubnoff et al., 2009) , which has previously been identified in a PKC412-resistant AML patient as the sole cause of drug resistance in the patient (Heidel et al., 2006) . FLT3-ITD-expressing cells resistant to SU5614 were characterized mainly by mutations in tyrosine kinase domain 2, predominantly in the D835 residue (von Bubnoff et al., 2009) , and FLT3-ITDexpressing cells resistant to sorafenib were unique to sorafenib in their resistance mechanisms, and included the F691L mutation in tyrosine kinase domain 1 and mutations in the Y842 residue in tyrosine kinase domain 2 (von Bubnoff et al., 2009) . PKC412, sunitinib and sorafenib, respectively, were generally able to override SU5614-resistant mutations in tyrosine kinase domain 2; however, the Y842D mutation was highly resistant to sorafenib (von Bubnoff et al., 2009) . In an independent study, the FLT3 inhibitor, SU5614, exhibited 7-to 26-fold more activity toward FLT3-ITD-expressing cells than FLT3-ITD-positive cells additionally harboring specific protein tyrosine kinase domain mutations (D835N and Y842H) acquired during selection in culture with increasing concentrations of SU5614 (Bagrintseva et al., 2004) .
Different inhibitors show varying potencies toward ITD mutations and activation loop mutants. For instance, sorafenib is more effective against FLT3-ITD than FLT3-D835Y, whereas sunitinib is equipotent toward both mutants (Kancha et al., 2007) . MLN518 shows widely variable activity in terms of inhibition of FLT3, STAT5 and ERK phosphorylation when tested against a panel of FLT3 activation loop mutants, including D835Y, D835A, D835E, D835H, D835N, D835V, D835del and I836del, with IC50s ranging from 500 nM to more than 10 mM (Clark et al., 2004) . In contrast, PKC412 shows relatively uniform and potent activity toward FLT3 activation loop mutants (Barry et al., 2007) .
Aberrant activation of growth and viability pathways
Previous models have suggested that AML is caused by two types of mutations (two hits): one that could promote growth and viability (type I), and another that could block terminal differentiation (type II). However, results from full genome sequencing indicate that AML is initiated by up to 20 different mutations and this simplified model may not sufficiently explain the molecular pathways that lead to disease development. Importantly, FLT3 mutations have been found in only a fraction of the AML cells, suggesting that they may be disease-promoting rather than initiating. Dysregulated pathways different from FLT3 signaling may therefore contribute to the growth of AML cells even during FLT3-targeted approaches.
FOXO3A. AML patients harboring FLT3 mutations have been found to have higher levels of phosphoprotein expression of the forkhead transcription factor, FOX-O3A (Kornblau et al., 2010) . This correlates with a poorer prognosis: higher rates of primary drug resistance and decreased duration of remission (Kornblau et al., 2010) . Indeed, FLT3-ITD has been implicated in the negative regulation of the FOXO3A transcription factor and promotion of cell viability by blocking Abbreviations: AML, acute myeloid leukemia; FLT3, Fms-Like Tyrosine kinase-3; ND, not determined. Asterisk refers to wt FLT3 phosphorylation.
Mechanisms of resistance to FLT3 inhibition E Weisberg et al FOXO3A-mediated apoptosis (Scheijen et al., 2004) . Specifically, FLT3-ITD expression in the murine Ba/F3 cell line leads to phosphorylation of FOXO3A, which stimulates translocation of FOXO3A from the nucleus into the cytoplasm and correlates with inhibition of FOXO target genes cylcin-dependent kinase inhibitor p27kip1 and proapoptotic Bim (Scheijen et al., 2004) . FLT3-ITD expression also correlates with phosphorylation and activation of ERK1/2, STAT5 and Akt (Scheijen et al., 2004; Brandts et al., 2005) .
STAT5/Pim pathway. Activation of the STAT5 transcription factor is thought to be important for the transformation of myeloid leukemia cells. In particular, the STAT5 target gene, PIM, may contribute to transformation. In vitro PIM-1 or PIM-2 cooperate with the MYC proto-oncogene and induce cell growth and viability (Wernig et al., 2008) . Thus, Pim may be another putative target for mutant FLT3-positive AML, as it has been found to be significantly downregulated on FLT3 inhibition (Kim et al., 2005) . Pim-1 expression also correlated with resistance to FLT3 inhibition (Kim et al., 2005) and has been identified as having a key role in the antiapoptotic effects of FLT3-ITD signaling through phosphorylation of BAD . These data suggest that FLT3-mediated upregulation of Pim-1 contributes to the antiapoptotic effects of FLT3 signaling. Evidence exists as well in support of the importance of Pim-2 expression for the survival of mutant FLT3-expressing cells (Adam et al., 2006) . (Piloto et al., 2007) . Inhibition of these signaling pathways in part reverses resistance to FLT3 inhibition (Piloto et al., 2007) . N-Ras mutations have also been found to evolve as part of the mechanism of resistance in FLT3 inhibitor-resistant cells (Piloto et al., 2007) .
Apoptosome. Apoptosome inhibition represents a mechanism whereby mutant FLT3-positive leukemic cells can exhibit chemoresistance. Constitutively activated kinases, such as mutant FLT3, BCR-ABL and TELPDGFRb, are able to inhibit the activity of the Apaf-1/ caspase-9 apoptosome, which mediates mitochondriarelated programmed cell death by altering the interaction between the apoptosome and the apoptosome inhibitor, Hsp90b (Kurokawa et al., 2008) .
Mediators of viability signaling pathways. Aberrant expression of antiapoptotic proteins is another mechanism of resistance to FLT3 inhibitors. For example, increased protein levels of the inhibitor of apoptosis (IAP), survivin, as well as activation of STAT1, STAT3 and STAT5, were observed in ABT-869-resistant MV4-11 cells (Zhou et al., 2009) , and antiapoptotic proteins were upregulated in PKC412-resistant MV4-11 cells (Stolzel et al., 2010) . Similarly, overexpression of antiapoptotic proteins of the BCL2 family has been found to mediate resistance to FLT3 inhibition in hematopoietic cells with activating FLT3 mutations Mechanisms of resistance to FLT3 inhibition E Weisberg et al (Kohl et al., 2007) and the antiapoptotic protein, MCL-1, was observed to be induced by a non-juxtamembrane ITD that has integrated into the b-2 sheet of the first kinase domain (FLT3_ITD627E) (Brietenbuecher et al., 2009) . In association with expression of FLT3-ITD and tyrosine kinase domain mutation dual mutants, which occurs in 1-2% of mutant FLT3-positive patients, there is induction of tyrosine kinase inhibitor and daunorubicin resistance through hyperactivation of STAT5 and consequent upregulation of Bcl-x(L) (Bagrintseva et al., 2005) . Similarly, strong phosphorylation of Bcl-2 antagonist of cell death (BAD) has been observed in mutant FLT3-and constitutively activated wild-type FLT3-expressing AML cells; siRNA knockdown of BAD expression in FLT3-ITD-expressing cells confers resistance to CEP-701 .
Gain-of-function mutations in CBL
Normally, FLT3 signaling is negatively regulated in part by the E3 ubiquitin ligase CBL. Phosphorylated FLT3 or related RTKs are recognized by the tyrosine kinasebinding domain (TKB) of CBL, leading to mono-or polyubiquitination of the target protein. This modification results in altered function or reduced stability (Thien and Langdon, 2005) . Recently, CBL has been identified as a frequent target of gain-of-function mutations in several myeloid neoplasias, including juvenile and chronic myelomonocytic leukemias (JMML and CMML), AML, myelodysplastic syndromes and myeloproliferative neoplasms (Caligiuri et al., 2007; Sargin et al., 2007; Dunbar et al., 2008; Grand et al., 2009; Loh et al., 2009; Makishima et al., 2009; Reindl et al., 2009; Sanada et al., 2009) . Mutations between the TKB and ring-finger domains, associated with acquired 11q uniparental disomy (Dunbar et al., 2008; Grand et al., 2009; Makishima et al., 2009; Sanada et al., 2009 ), lead to a loss of the E3 ligase activity (Sargin et al., 2007) . Even though these mutations require the expression of a functional RTK for factor-independent growth (Sargin et al., 2007; Grand et al., 2009) , it is not known whether a loss of E3 activity is sufficient for this phenotype. In this context, it should be noted that mice with CBL gene disruption are not known to be associated with ligand-independent RTK activation (Murphy et al., 1998; Naramura et al., 1998) . Thus, even though mutated CBL gains a new function by supporting transformation of hematopoietic cells, the loss of its E3 ligase activity may be essential but not sufficient for this phenotype. In normal signaling, CBL is not known to be involved in ligand-independent receptor activation and it is likely that this new putative function alters its interaction with signaling partners.
Transforming forms of CBL have the potential to interact with different RTKs and other signaling molecules. For example, Sanada et al. (2009) recently suggested that cells in the absence of CBL are hyperproliferative in response to stem cell factor, thrombopoietin, interleukin 3 (IL-3) and FLT3 ligand. Targeting FLT3 alone may therefore still lead to activation of CBLdependent pathways that increase growth or viability. It will be important to understand how mutant CBL leads to activation of FLT3 and related pathways to develop new therapeutic approaches.
FLT3 ligand FLT3 ligand expression was observed to be upregulated in MV4-11 cells made resistant to the FLT3 inhibitor, ABT-869, for a prolonged period of time (Zhou et al., 2009) . This elevated expression led to increased protein levels of the IAP, survivin, as well as activation of STAT1, STAT3 and STAT5. In addition, blocking FLT3 ligand with an FLT3 ligand-neutralizing antibody was observed to enhance the proapoptotic activity of ABT-869 against ABT-869-resistant cells (Zhou et al., 2009) . Another study of resistance in MV4-11 cells made resistant to PKC412 revealed acquisition of clonal alternations at chromosome 13q, additional FLT3 signaling, and changes in gene expression before and after treatment with PKC412, including that of FLT3 ligand (Stolzel et al., 2010) .
The concentration of FLT3 ligand has been observed to be elevated in the plasma of cancer patients that have been treated with chemotherapy or radiotherapy (Lyman et al., 1995; Wodnar-Filipowicz et al., 1996; Zwierzina et al., 1999; Bojko et al., 2002) . In the case of AML, this is predicted to impede the efficacy of FLT3 inhibitors given after chemotherapy. This phenomenon has been replicated in animal models: Significantly elevated FLT3 ligand levels were observed in the serum of mice treated with the chemotherapeutic agent busulphan (Molyneux et al., 2008) .
Protection by the stromal cell microenvironment Bone marrow stroma and stromal cell-derived factors have been implicated in the long-term survival and growth of various hematological malignancies, including precursor B-ALL ( (Ashley et al., 1994; Bradstock et al., 1996) . Bone marrow stroma has also been shown to prevent programmed cell death of AML and chronic lymphocytic leukemia cells (Lagneaux et al., 1998 (Lagneaux et al., , 1999 Konopleva et al., 2002) . In addition, splenic stroma and splenocytes support the viability and proliferation of both normal and malignant hematopoiesis (Shaked et al., 2005; Despars and O'Neill, 2006) . Furthermore, leukemic lymphoblasts that are coupled to bone marrow stroma through gap junction communication are believed to be held in a quiescent, nondividing state, which is thought to contribute to resistance to antimitotic agents (Paraguassu´-Braga et al., 2003) .
A flow cytometry-based assay system demonstrated enhancement of CD34( þ )CD38(-)CD123( þ ) leukemic stem and progenitor cell survival in response to treatment with Ara-c and the FLT3 inhibitor, AG1296, respectively, when cells were drug treated under defined 'niche-like' (or microenvironmental support) conditions (Mony et al., 2008) . The defined 'nichelike' microenvironment in this study was comprised of serum-free medium supplemented with IL-3, IL-6, stem cell factor and Ang-1, and also included immobilized fibronectin. Contrary to the drug resistance observed with Ara-c and AG1296 in the presence of a 'niche-like' microenvironment, AML cells were more sensitive to inhibitors of signaling pathways, such as the MAPK inhibitor, U0126, the JAK-STAT inhibitor, AG490, and the PI3K inhibitor, Wortmannin, under the same 'nichelike' conditions.
In nilotinib-treated mice, high tumor burden/residual disease has been identified in tissues characterized as significant sources of hematopoiesis-promoting stroma; the pattern of leukemia distribution in mice was consistent with what is observed in imatinib/nilotinibtreated CML patients (Weisberg et al., 2008c) . Stromal protection of leukemic cells from the inhibitory effects of nilotinib and PKC412 has been observed, and stromal-secreted viability factors have been identified, including IL-6 and GM-CSF, as possibly having a role in stromal-mediated cytoprotection of tyrosine kinase inhibitor-treated leukemia cells (Weisberg et al., 2008c (Weisberg et al., , 2009 ). These results may help to explain why FLT3 inhibitors such as CEP-701 and PKC412 are clinically able to deplete blasts in the peripheral blood, but are less effective against blasts in the marrow (Smith et al., 2004; Stone et al., 2005a, b) .
Pgp
Antiapoptotic p-glycoprotein (pgp), a membrane efflux pump, is another putative target for drug-resistant, mutant FLT3-positive AML. Pgp expression in FLT3-ITD-positive cells reduces the activity of inhibitors such as herbimycin A and AG1296 (Hunter et al., 2004) . Contrary to this, however, PKC412 showed activity against pgp-and FLT3-ITD-positive cells (Hunter et al., 2004) , which suggests that pgp expression only contributes to drug resistance involving certain select inhibitors.
Mutant FLT3 and resistance to chemotherapy. There is evidence in support of mutant FLT3 itself contributing to resistance of AML to chemotherapeutic agents. For instance, in a study in which FLT3-ITD was introduced into myeloid cell lines, FLT3-ITD expression was observed to correlate with Ara-c resistance due to decreased cellular uptake of Ara-c (Jin et al., 2009) . Drug resistance was accompanied by downregulation of a transporter responsible for Ara-C cellular uptake, equilibrative nucleoside transporter 1 (ENT1), possibly mediated by upregulation of hypoxia-inducible factor 1 alpha subunit (HIF1A) (Jin et al., 2009) . Pretreatment with PKC412 reversed the reduced cellular uptake of Ara-c in FLT3-ITD-expressing myeloid cells (Jin et al., 2009) .
Also supporting the notion of resistance of FLT3-ITD to chemotherapy is an investigation assessing mutant FLT3 expression in a group of Korean patients, in which FLT3-ITD was detected in a subset of patients that failed to achieve remission (Bang et al., 2008) . In contrast, 93 patients that were in remission tested negative for FLT3-ITD expression (Bang et al., 2008) .
Finally, an extensive characterization of ITDs in a group of AML patients was carried out in terms of their site of insertion (that is, juxtamembrane domain, juxtamembrane domain hinge region, b-1 sheet of the tyrosine kinase domain-1 and the residual tyrosine kinase domain-1), length of the ITD and influence on patient prognosis (Kayser et al., 2009) . The integration of the ITD in the b-1 sheet was found to be a negative prognostic indicator in terms of survival and remission, and thus is believed to have a role in resistance to chemotherapy (Kayser et al., 2009 ).
FLT3-ITD and genomic instability. Little is known about the molecular mechanisms that regulate genomic instability in AML, but active forms of FLT3 are thought to promote the occurrence of additional mutations. These mutagenic events are caused by a two-phase process, whereby initially DNA is damaged, and then in a second step the damage is failed to be appropriately repaired. In addition to exogenous factors, oxidative stress has been recognized as a significant contributor to DNA damage. Intracellular reactive oxygen species (ROS) have the potential to damage DNA, leading to direct oxidation or DNA strand breaks . Consistent with this model, FLT3-ITD has been shown to induce ROS production, as well as DNA damage and decreased fidelity of DNA repair (Sallmyr et al., 2008) . Cells transformed by FLT3-ITD and other oncogenic tyrosine kinases are also associated with increased mutagenic single-strand annealing (SSA), a repair process that involves sequence repeats (Cramer et al., 2008; Fernandes et al., 2009) . Mutagenic SSA depends on the transforming kinase activity but may be increased by stromal-derived factors, even in the presence of kinase inhibitors (Fernandes et al., 2009 ). An increased rate of mutagenic events is likely to be the cause of drug resistance associated with disease progression in AML. The particular defect that is involved in the mechanism causing drug resistance may be difficult to pinpoint and it is possible that a combination of events are causal factors.
Approaches to overriding drug resistance
Combined treatment using FLT3 inhibitors and chemotherapeutic agents It has been shown that, in at least some primary AML cells, there is continued phosphorylation of ERK, STAT5 or AKT following inhibition of FLT3-ITD, which may contribute to the limited efficacy of FLT3 inhibitors used as single agents for the treatment of mutant FLT3-positive AML (Siendones et al., 2007) . In addition, it has recently been shown that FLT3-ITD inhibition of autophosphorylation does not always result in cell death, which raises the question of the importance of FLT3 signaling for some mutant FLT3-positive AML (Pratz et al., 2010) .
The effectiveness of combined treatment using an FLT3 inhibitor and chemotherapeutic agents may, at least in part, rest in the ability of FLT3 inhibitors, such as PKC412, to inhibit repair of chemotherapyinduced DNA damage, in effect reversing the drugresistant phenotype of mutant FLT3-expressing cells and diminishing the risk of relapse (Seedhouse et al., 2006) . Indeed, preclinical studies have shown that the FLT3 inhibitor, SU11657, increases the median survival of leukemic mice when used in combination with doxorubicin (Lee et al., 2007) . In related manner, FLT3 inhibitors such as PKC412 and CEP-701 are being investigated in late-stage clinical trials for AML in conjunction with the use of standard chemotherapy.
Utilization of signaling pathway inhibitors
The combination of selective inhibitors of mediators of major signaling pathways with FLT3 inhibition offers considerable potential clinical benefit. For example, the dual PI3K/PDK-1 inhibitor, BAG956 (Weisberg et al., 2008a) , the farnesyl-transferase inhibitor, lonafarnib (Mollgard et al., 2008) and rapamycin (Mohi et al., 2004) have the ability to effectively combine with PKC412 to kill drug-sensitive and insensitive mutant FLT3-expressing cells. The rapamycin derivative, RAD001, augments the antileukemic activity of the FLT3 kinase inhibitor, sunitinib (Ikezoe et al., 2006) , as does the MEK1/2 kinase inhibitor, AZD6244 (ARRY-142886) (Nishioka et al., 2008) . The multiple kinase inhibitor, KP372-1, inhibits the kinase activity of AKT, PDK1 and FLT3, and kills AML cells in a manner mediated by Pim-1 downregulation (due to FLT3 inhibition), mitochondrial dysfunction, and inhibition of phosphorylation of downstream PI3K/AKT signaling components, such as p70S6 kinase (Zeng et al., 2006b) .
Targeting bone marrow microenvironment
In addition to identifying and developing potent kinase inhibitors representative of novel and unique structural classes with the ability to override drug resistance due to changes in the target protein, there is a push toward gaining a better understanding of the mechanisms underlying drug resistance in CML and AML as they relate to the leukemic cell microenvironment. Clinical trial data with tyrosine kinase inhibitors show that although the peripheral blood of patients responds well, bone marrow responds less well (Smith et al., 2004; Stone et al., 2005a, b) . It appears possible that small numbers of leukemic CD34 þ cells can persist in the marrow microenvironment of leukemia patients after years of therapy with kinase inhibitors. Stromal cells have been implicated, as they provide viability signals to leukemic cells that protect them from inhibitor effects. Indeed, the quantity of leukemic stem cells that rely on stroma to survive is predictive of disease outcome (Kumagai et al., 1996) . Thus, deregulated signaling molecules associated with viability/apoptotic signaling represent attractive targets for therapeutic intervention, and several strategies have emerged that may be effective in preventing drug resistance due to this.
One approach involves combining targeted inhibitors with small molecule inhibitors of key components of major signaling pathways affecting the viability/expansion of leukemic cells, such as agents that block the activity of IAPs. These inhibitors are based on the structure of second mitochondria-derived activator of caspase (Smac), which mediates programmed cell death through the intrinsic apoptotic pathway and binds to and inhibits the IAP family of proteins (Liu et al., 2000; Wu et al., 2000) .
Recent study has indicated that IAP inhibitors can target multiple IAPs (that is, XIAP, c-IAP) to enhance the activity of different proapoptotic signaling pathways (Galban et al., 2009) . However, the role of XIAP in intrinsic versus extrinsic death pathways is unclear; recent studies suggest that it has a more significant role in regulating death receptor-mediated apoptosis than intrinsic pathway-mediated cell death (Sensintaffar et al., 2010) .
Accordingly, effective IAP inhibitors have been developed, such as LBW242 (Weisberg et al., 2007) , which bind to and inhibit multiple IAPs (that is, XIAP, c-IAP) to enhance the activity of different proapoptotic signaling pathways. The development of the proapoptotic IAP inhibitor, LBW242 (Novartis), a 3-mer and Smac mimetic, was based on the ability of the N-terminal seven amino acids of Smac to neutralize the BIR3 domain of XIAP (Liu et al., 2000; Wu et al., 2000) . LBW242 was the result of a rational drug design effort based on Smac 4-mer, and has been found to display nM potency against XIAP and CIAP1 in a competitive binding assay with Smac 7-mer. LBW242 also kills cells in a manner strictly dependent on caspases, and death is accompanied by PARP cleavage, annexin positivity and accumulation of cells in subG1. The ability of LBW242 to synergize with PKC412 has been demonstrated in vivo against progressive mutant FLT3-positive leukemia and to override stromal-mediated chemoresistance in vitro (Weisberg et al., 2007) .
Another strategy for overriding stromal-mediated chemoresistance is the use of inhibitors of the chemokine receptor, CXCR4, which mediates the migration of hematopoietic cells to the bone marrow and has a key role in leukemic cell-stromal cell interactions. Mutant FLT3 activates CXCR4 signaling, and CXCR4 inhibition partially overcomes stromal-mediated cytoprotection of FLT3 inhibitor-treated AML cells (Zeng et al., 2009) . In vivo, the CXCR4 inhibitor, AMD3465, lowered leukemia burden and enhanced survival through mobilization of AML cells and progenitor cells into circulation, and potentiation of the antileukemic effects of the FLT3 inhibitor, sorafenib, and chemotherapy (Zeng et al., 2009) . The polypeptide, RCP168, which antagonizes SDF-1a-or stromal cell-induced chemotaxis of leukemic cells, was also shown to significantly augment chemotherapy-induced apoptosis in stromacocultured mutant FLT3-expressing cells (Zeng et al., 2006a) . Another promising strategy would be to target pathways that regulate receptor recycling. A recent paper (Grundler et al., 2009) suggests that PIM kinase mediates surface expression of CXCR4, which suggests that targeting PIM/FLT3 would be a more efficient therapy for targeting the bone marrow microenvironment. Thus, the use of CXCR4 inhibitors may be a potentially useful approach to overriding stromalmediated chemoresistance.
Mechanisms of resistance to FLT3 inhibition E Weisberg et al
Antibody and siRNA therapy Target-specific antibodies represent one approach to overriding drug resistance by potentially enhancing the efficacy of FLT3 inhibitors. For instance, the novel FLT3-directed antibody, IMC-EB, has been shown to inhibit growth of leukemia cells expressing wild-type or constitutively activated FLT3 (Youssouflan et al., 2010) . Another therapeutic approach would be the use RNA interference to knockdown FLT3 expression. For example, FLT3-targeted siRNA has been shown to induce apoptosis in FLT3-ITD-expressing cells and to increases the activity of the FLT3 inhibitor, MLN518 . However, the difficulties to efficiently deliver these molecules in vivo have not yet been overcome.
Drug resistance in mutant FLT3-positive pediatric AML
As pediatric AML has a poor prognosis, novel therapies are needed. A potentially clinically significant target in pediatric AML is the FLT3 tyrosine kinase, as FLT3-ITD or FLT3 point mutants are found in 17-24% of pediatric AML cases and FLT3-ITD mutations confer a particularly poor prognosis in pediatric AML patients (Stirewalt and Radich, 2003) . Constitutively activated FLT3 occurs most frequently as ITD mutations, and is observed in B15% of pediatric AML patients and 20-25% of adult AML patients (Nakao et al., 1996) . As with adults, the prevalence of point mutation of the activation loop domain in pediatric AML patients is 7% .
In a large pediatric study involving 630 children with de novo AML, FLT3-ITD mutations were found in 12% of the patients, and FLT3 activation loop domain mutations were observed in B7% of patients, with poorer progression-free survival associated with FLT3-ITD (Meshinchi et al., 2006) . In a study involving 234 pediatric AML patients, FLT3-ITD mutations were found in 11.5% of patients who were classified as significantly older with lower remission induction rates and lower 5-year probability rates of event-free survival (Zwaan et al., 2003) . High ratios between mutant and wild-type FLT3 appeared to worsen prognosis in these patients (Zwaan et al., 2003) . However, although FLT3-ITD proved to be a strong adverse prognostic factor in this study, it did not appear to be associated with increased cellular drug resistance in vitro (Zwaan et al., 2003) . Clinical outcome has been found to be worse for pediatric AML patients harboring CD34( þ )CD33(À) precursors that are FLT3-ITD positive, suggesting that FLT3-ITD expression in this primitive cell population may be coupled to resistance (Pollard et al., 2006) .
The physical characteristics of the ITD in mutant FLT3-positive pediatric patients may have a role in response to therapy. In a study of 77 FLT3-ITDpositive pediatric patients, 77% had a single ITD, 21% had 2 ITDs and 3% had 3 ITDs; the presence of >1 ITD was not found to be clinically significant (Meshinchi et al., 2008) . In all cases, there was duplication of amino-acid residues Y591-Y597, which encodes the switch and zipper regions of the juxtamembrane domain of FLT3 (Meshinchi et al., 2008) . The longer length of ITDs in these patients was associated with a worse relapse-free survival (Meshinchi et al., 2008) .
Importantly, pediatric AML primary samples with FLT3-ITD mutations were found to be preferentially killed by FLT3 inhibition (Brown et al., 2004) . FLT3 inhibitors, such as PKC412, have been tested mainly in adults and have shown clinical activity, although as described above, this is generally in the form of transient reductions in blast counts in peripheral blood or bone marrow. There are presently ongoing Phase I/II clinical trials studying the safety and preliminary efficacy of oral PKC412 in relapsed or refractory pediatric leukemia (children under the age of 18 years), including patients with mutant FLT3-positive AML. Drug development studies in pediatric AML, however, are generally complicated by the small number of patients available for such studies, as well as the lack of interest on the part of pharmaceutical companies to carry out pediatric studies due to the existence of a small market. This reality makes it crucial to optimize new therapeutic strategies for AML that are being explored in adults, and that may soon be of interest and importance to pediatric patients.
Conclusion
There is a pressing need for the identification and development of new therapeutic approaches that could lead to improved clinical responsiveness in AML patients. A better understanding of mechanisms of resistance to FLT3 inhibitors, such as those associated with stromal-mediated cyto-protection and upregulation of antiapoptotic signaling factors, will aid in the discovery and design of more effective treatment strategies. Novel approaches to overriding drug resistance include antibody therapy, and the combined use of FLT3 inhibitors with inhibitors of viability signaling or components of PI3K/Akt, MAPK and JAK/STAT pathway signaling. Each novel strategy carries with it the potential to bring clinicians closer to overriding existing challenges in the treatment of mutant FLT3-positive AML.
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